Track market-moving stories before they get noisy

MetLife Investment Management (“MIM”), the institutional asset management business of MetLife, Inc. (NYSE: MET), together with development partner ZOM Livi

Posted by Defense World Staff on Jul 20th, 2026

Boston Common Asset Management LLC trimmed its position in MetLife, Inc. (NYSE:MET – Free Report) by 11.2% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 109,516 shares of the financial services provider’s stock after selling 13,810 shares during the quarter. Boston Common Asset Management LLC’s holdings in MetLife were worth $7,745,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Brighton Jones LLC lifted its position in MetLife by 9.0% during the fourth quarter. Brighton Jones LLC now owns 4,240 shares of the financial services provider’s stock valued at $347,000 after buying an additional 351 shares in the last quarter. Caxton Associates LLP acquired a new stake in shares of MetLife in the first quarter worth $307,000. Empowered Funds LLC raised its stake in shares of MetLife by 187.6% in the 1st quarter. Empowered Funds LLC now owns 33,378 shares of the financial services provider’s stock valued at $2,680,000 after acquiring an additional 21,771 shares during the period. Sivia Capital Partners LLC purchased a new position in shares of MetLife in the 2nd quarter valued at $404,000. Finally, Jump Financial LLC acquired a new position in shares of MetLife during the 2nd quarter valued at $444,000. Hedge funds and other institutional investors own 94.99% of the company’s stock.

MetLife Stock Performance NYSE:MET opened at $93.99 on Monday. The firm has a 50-day moving average of $85.80 and a two-hundred day moving average of $79.07. The company has a debt-to-equity ratio of 0.53, a current ratio of 0.20 and a quick ratio of 0.20. The stock has a market cap of $60.48 billion, a P/E ratio of 18.21, a PEG ratio of 0.72 and a beta of 0.78. MetLife, Inc. has a 1-year low of $67.33 and a 1-year high of $94.86.

MetLife (NYSE:MET – Get Free Report) last announced its earnings results on Wednesday, May 6th. The financial services provider reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.27 by $0.15. MetLife had a return on equity of 22.60% and a net margin of 4.66%.The business had revenue of $14.18 billion for the quarter, compared to analyst estimates of $19.49 billion. The company’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.96 earnings per share. On average, research analysts expect that MetLife, Inc. will post 9.94 earnings per share for the current fiscal year.

MetLife Announces Dividend The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 4th will be issued a dividend of $0.5925 per share. The ex-dividend date is Tuesday, August 4th. This represents a $2.37 annualized dividend and a yield of 2.5%. MetLife’s payout ratio is currently 45.93%.

Wall Street Analysts Forecast Growth A number of analysts recently weighed in on the stock. Morgan Stanley upped their price target on shares of MetLife from $93.00 to $103.00 and gave the stock an “overweight” rating in a research report on Monday, July 6th. Bank of America cut their price objective on MetLife from $103.00 to $99.00 and set a “buy” rating on the stock in a research report on Tuesday, April 14th. Wall Street Zen cut MetLife from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Weiss Ratings raised MetLife from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday, June 15th. Finally, Keefe, Bruyette & Woods increased their target price on MetLife from $98.00 to $105.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $98.57.

Check Out Our Latest Report on MetLife

Key Stories Impacting MetLife Here are the key news stories impacting MetLife this week:

Positive Sentiment: MetLife Stadium is hosting the World Cup final, which keeps the venue in the global spotlight and may highlight the company’s high-profile asset and brand visibility. FIFA insists MetLife Stadium’s pitch is ready for the World Cup final despite criticism Positive Sentiment: Heavy media coverage around ticket sales, fan guides, food and drink pricing, and kickoff details suggests strong interest and traffic around the event at MetLife Stadium. How to buy tickets to see Spain in World Cup Final at MetLife Neutral Sentiment: News about weather, heat, storms, air quality, and wildfire smoke could affect the event experience, but it does not directly change MetLife’s earnings outlook. World Cup final could be shaped by heat, storms and air quality at MetLife Stadium Neutral Sentiment: FIFA’s criticism of the pitch and the “money grab” controversy may create headline risk for the venue, but the impact on MetLife’s stock is likely limited unless the issue affects operations or reputation more broadly. NJ governor slams FIFA’s money grab over sales of MetLife World Cup pitch Negative Sentiment: Ongoing criticism about the field quality and pitch conditions at MetLife Stadium could dent the venue’s reputation, even though it is unlikely to materially affect MetLife’s insurance business. The MetLife trap: the controversial pitch threatening the final | OneFootball MetLife Profile (Free Report)

MetLife, Inc is a global provider of insurance, annuities and employee benefit programs. Headquartered in New York City, the company offers a range of risk protection and retirement solutions to individuals, employers and institutional clients. Its core businesses include life insurance, group benefits, retirement products such as annuities, and supplemental health products including dental and disability coverage.

In addition to traditional life and group insurance, MetLife provides workplace benefits and voluntary products distributed through employer-sponsored programs.

Read More Five stocks we like better than MetLife Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand Rises 3 Aerospace Suppliers That Could Benefit as Aircraft Makers Face Bottlenecks

Receive News & Ratings for MetLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEMicron Technology, Inc. $MU Holdings Lowered by Boston Common Asset Management LLC

Key Takeaways MetLife is embedding AI across core operations to improve efficiency and customer experiences.MET invested $3.2 billion in technology over five years to support enterprise-wide AI adoption.MET's Q1 2026 adjusted EPS rose 23.5% YoY, while its direct expense ratio improved to 11.9%. MetLife, Inc. (MET - Free Report) is increasingly embedding artificial intelligence (AI) across its business as part of its New Frontier strategy, with the goal of improving efficiency, enhancing customer experiences and supporting long-term growth. Rather than treating AI as a standalone initiative, the insurer is integrating the technology into core operations, from underwriting and claims to customer service and decision-making. This approach is helping the company simplify workflows while positioning it to compete more effectively in an evolving insurance market.

MetLife has invested more than $3.2 billion over the past five years to modernize its technology infrastructure. These investments are enabling broader AI adoption across the enterprise. AI tools are helping employees make faster decisions, reduce operational friction and deliver more personalized customer interactions. MetLife continues to emphasize responsible AI deployment through robust governance and risk management practices.

The company's AI investments are already supporting stronger operating performance. In the first quarter of 2026, adjusted earnings per share (EPS) increased 23.5% year over year to $2.42. At the same time, MetLife's direct expense ratio, excluding total notable items related to direct expenses and PRT, improved to 11.9% from 12% a year ago, reflecting continued productivity gains and disciplined cost management.

AI is becoming more than an operational tool for MetLife — it is evolving into a strategic differentiator. By combining technology-driven efficiency with disciplined execution and a diversified business model, the company is positioning itself to improve productivity, strengthen customer relationships and build a sustainable competitive advantage over the long run.

How Are Competitors Faring?Some of MET’s competitors adopting AI to improve operations include American International Group, Inc. (AIG - Free Report) and CNO Financial Group, Inc. (CNO - Free Report) .

AIG is expanding its use of AI to improve underwriting accuracy, automate claims handling and strengthen risk assessment. American International Group is also using generative AI to support employees and streamline workflows, helping improve operational efficiency while delivering faster and more personalized customer service.

CNO Financial is adopting AI and advanced analytics to modernize customer engagement, automate routine processes and improve agent productivity. CNO is also investing in digital capabilities that simplify policy servicing and support more personalized insurance solutions, strengthening its long-term operating efficiency.

MET’s Price Performance, Valuation & EstimatesIn the year-to-date period, MET’s shares have risen 17.3% compared with the industry’s growth of 4.9%.

Image Source: Zacks Investment Research

From a valuation standpoint, MET trades at a forward price-to-earnings ratio of 8.80, above the industry average of 8.27. MetLife carries a Value Score of A.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for MET’s 2026 earnings implies 13% growth from the year-ago period.

Image Source: Zacks Investment Research

MetLife currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) today announced that its board of directors has declared a third quarter 2026 common stock dividend of $0.5925 per share. The dividend will be payable on September 8, 2026, to shareholders of record as of August 4, 2026. About MetLife MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates (“MetLife”), is one of the world's leading financial services companies, providing insurance, annuities, employee benefits and asset management.

WHIPPANY, N.J.--(BUSINESS WIRE)--MetLife Investment Management (MIM), the institutional asset management business of MetLife, Inc. (NYSE: MET), today announced that Chris Aiken has been appointed head of Real Estate Equity Strategies, effective immediately. He will report to Andrea Drasites, global head of Real Estate and Agricultural Finance.

“Chris is an integral part of our real estate platform and has consistently demonstrated strong leadership skills, deep market expertise and a commitment to delivering value for our clients,” said Brian Funk, president of MIM. “His experience across acquisitions, development and portfolio strategy, combined with his collaborative style, positions him well to lead our Real Estate Equity Strategies business as we continue to advance the platform.”

As head of Real Estate Equity Strategies, Aiken will lead MIM’s direct property investment platform and oversee investing activities on behalf of MetLife’s general account and third-party institutional investors across core, core-plus, build-to-core, value-add and opportunistic strategies.

MIM’s real estate portfolio represented $106.2 billion in assets under management as of March 31, 2026.1 The announcement follows the appointment of Andrea Drasites as global head of Real Estate and Agricultural Finance, reflecting the firm’s continued investment in its real estate capabilities and leadership team as it expands its global platform.

Prior to assuming this role, Aiken served as head of Acquisitions for MIM’s Real Estate Equity Strategies Group. Before joining MIM, he was a Managing Director at Safanad, where he led all aspects of the investment lifecycle across multiple real estate strategies. He also held real estate investment roles at BlackRock and Salomon Smith Barney.

Aiken earned an M.S. in Real Estate Finance from New York University and a B.A. in Business Administration from Morehouse College. He is a member and co-chair of the Membership Committee for the Real Estate Executive Council and a member of the Urban Land Institute’s Urban Development Mixed-Use Council.

About MetLife Investment Management

MetLife Investment Management, the institutional asset management business of MetLife, Inc. (NYSE: MET), provides tailored investment management solutions to institutional investors worldwide. MetLife Investment Management has long-established global expertise in public fixed income, private fixed income, real estate, equity, alternatives, multi-asset, and insurance solutions and provides public and private pension plans, insurance companies, endowments, funds and other institutional clients with a range of bespoke investment solutions that seek to meet a range of long-term investment objectives and risk-adjusted returns over time. MetLife Investment Management has over 150 years of investment experience and, as of March 31, 2026, had $736.3 billion in total assets under management. For more information, see MetLife Investment Management’s Total Assets Under Management fact sheet for the quarter ended March 31, 2026 available on MetLife’s Investor Relations web page (https://investor.metlife.com).

About MetLife

MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates (“MetLife”), is one of the world’s leading financial services companies, providing insurance, annuities, employee benefits and asset management to help individual and institutional customers build a more confident future. Founded in 1868, MetLife has operations in more than 40 markets globally and holds leading positions in the United States, Asia, Latin America, Europe and the Middle East. For more information, visit https://www.metlife.com.

Forward-Looking Statements

The forward-looking statements in this news release, using words such as “continue,” “positions,” “seek” and “will,” are based on assumptions and expectations that involve risks and uncertainties, including the “Risk Factors” MetLife, Inc. describes in its U.S. Securities and Exchange Commission filings. MetLife’s future results could differ, and it does not undertake any obligation to publicly correct or update any of these statements.

1 At estimated fair value. Mortgage loans, real estate and real estate joint ventures are included at net asset value, net of deduction for encumbering debt and have been adjusted from carrying value to estimated fair value.

NEW YORK--(BUSINESS WIRE)--For many pet parents, saying goodbye to a beloved dog or cat is one of life’s most difficult experiences. MetLife Pet Insurance is introducing a new Memorial Tree Program to help honor that bond, alongside grief counseling services that support pet parents through end-of-life decisions and the months that follow.

MetLife Pet Insurance is introducing a new Memorial Tree Program to help honor pets, alongside grief counseling services that support pet parents through end-of-life decisions.

Share MetLife Pet Insurance research underscores the depth of that bond: 95% of Americans consider their pet to be family, and 50% say they have grieved a pet’s death more deeply than a human loved one, underscoring the need for support that addresses both the emotional and practical aspects of loss.

Through a collaboration with the National Forest Foundation, MetLife Pet Insurance will honor every insured pet that passes away by supporting the planting of a tree in a U.S. National Forest. Policyholders who cancel coverage due to the death of a pet will receive a sympathy card noting that a memorial tree will be planted in their pet’s honor.

The program builds on MetLife Pet Insurance’s existing grief counseling services, provided by TELUS Health, which connect eligible policyholders with trained counselors for guidance during end-of-life decisions and in the months that follow.

“Pets are family, and the loss of a pet can be one of the most emotional experiences a person can face,” said Brian Jorgensen, head of MetLife Pet Insurance. “We’re focused on showing up for pet parents during that time, not only by helping them honor their pets, but by offering support when they need it most.”

The initiative reflects a broader focus on emotional well-being across MetLife’s offerings. Through its group life offerings, MetLife also provides grief counseling and emotional wellness services through TELUS Health as part of the MetLife Advantages program, reinforcing a consistent approach to care across life and pet insurance.

The National Forest Foundation leads one of the largest reforestation efforts in the United States, restoring forests impacted by wildfire, disease and other environmental challenges.

The Memorial Tree Program is expected to launch in June 2026.

About MetLife Pet Insurance Solutions, LLC

MetLife Pet coverage is issued by Metropolitan General Insurance Company, a Rhode Island insurance company headquartered at 700 Quaker Lane, Warwick, RI 02886. MetLife Pet Insurance Solutions LLC is the policy administrator. It may operate under an alternate or fictitious name in certain jurisdictions, including MetLife Pet Insurance Services LLC (New York and Minnesota) and MetLife Pet Insurance Solutions Agency LLC (Illinois). For more information, visit https://www.metlifepetinsurance.com.

About MetLife

MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates (“MetLife”), is one of the world’s leading financial services companies, providing insurance, annuities, employee benefits and asset management to help individual and institutional customers build a more confident future. Founded in 1868, MetLife has operations in more than 40 markets globally and holds leading positions in the United States, Asia, Latin America, Europe and the Middle East. For more information, visit www.metlife.com. 

More News From MetLife, Inc.

-

Opening represents a revitalized era of seamless travel and economic investment for Greater Montreal

LONGUEUIL, Quebec--(BUSINESS WIRE)--Porter Airlines is launching its first flights from Montreal Metropolitan Airport - MET, a significant, privately-funded national transportation infrastructure project, located in Longueuil on Montreal’s South Shore. The airport’s close proximity to downtown will meaningfully contribute to increasing air access for one of Canada’s most prominent cities. Four inaugural routes begin today: with Vancouver, Toronto-Pearson, Toronto-City, and St. John’s, N.L.

Over the next week, Porter is introducing flights to 11 airports across the country from MET, just in time for the summer travel season. Passenger traffic at MET is projected to hit one million in its first year, climbing to four million annually at full capacity.

MET routes*

Start date

Frequency

St. John’s (YYT) **

June 15

7x weekly

Toronto City (YTZ)

June 15

27x weekly

Toronto Pearson (YYZ)

June 15

20x weekly

Vancouver (YVR)

June 15

14x weekly

Edmonton (YEG)

June 16

7x weekly

Calgary (YYC)

June 17

7x weekly

Halifax (YHZ)

June 17

14x weekly

Charlottetown (YYG) **

June 18

7x weekly

Winnipeg (YWG) **

June 18

7x weekly

Moncton (YQM) **

June 19

7x weekly

Hamilton (YHM)

June 22

14x weekly

  *Note: MET’s official airport designation code is YHU
**Seasonal route

Flights can be booked at www.flyporter.com and through travel agencies.

This launch marks a historic moment for Montreal’s air travel sector, offering Montrealers and visitors greater flexibility for travelling throughout Canada. Improved air connectivity also strengthens Montreal’s economic development, stimulating trade and business opportunities.

With new service from MET and continued operations at Montreal-Trudeau Airport, Porter is set to nearly double its capacity in Greater Montreal this summer, adding over 1,000 flights. Moreover, a partnership with Pascan Aviation will boost regional connections across Quebec, the Maritimes, and Porter’s broader North American network.

Porter is recognized as one of North America’s top airlines, known for its refined, attentive service and complimentary amenities. This includes premium snacks, a selection of beverages, including beer and wine served in glassware, and fast, free WiFi on its E195-E2 aircraft.

MET will be served by Porter’s fleet of De Havilland Dash 8-400s (78 seats) and Embraer E195-E2s (132 seats), which are among the quietest and most fuel-efficient aircraft in their respective classes. Both feature a two-by-two seating configuration, with no middle seats, for enhanced comfort.

Quotes

“Starting new routes is something that we often do, but launching 11 at once from a new airport to transform a city’s connectivity is exceptional. This is truly meaningful for Montreal’s people, economy and tourism, and we’re proud to be a part of it. Demand is already exceeding our expectations, and as soon as travellers discover Porter’s unique offering, combined with MET’s comfort and convenience, they will have a new appreciation for air travel.”

- Michael Deluce, CEO, Porter Airlines

“This new terminal is the result of a collaborative process involving citizens and elected officials, a process that began long before the ground-breaking ceremony. Today, we are proud to see that 80% of the population on Montreal’s South Shore supports the MET project.”

- Simon-Pierre Diamond, interim president of MET – Montreal Metropolitan Airport

“We are proud to welcome Porter Airlines to YHU Terminal at MET- Montreal Metropolitan Airport and to support the expansion of its network in Greater Montreal. Together, we are offering travellers an experience that combines Porter’s renowned service with a terminal specifically designed to provide a faster, more seamless and more comfortable journey from curb to gate.”

- Charles Roberge, president and Chief Executive Officer, YHU Terminal

About Porter

Since 2006, Porter Airlines has been elevating the experience of economy air travel for every passenger, providing genuine hospitality with style, care and charm. Porter’s fleet of Embraer E195-E2 and De Havilland Dash 8-400 aircraft serves North America, including a coast-to-coast domestic Canadian network, the U.S., Mexico, the Caribbean and Central America. Headquartered in Toronto, Porter is an Official 4 Star Airline® in the World Airline Star Rating®. Visit www.flyporter.com or follow @porterairlines on Instagram, Facebook and X.

More News From Porter Airlines

Back to Newsroom

MarketBeat Instant News Alerts

2 hours ago

Insider Selling: MarketAxess (NASDAQ:MKTX) General Counsel Sells 100 Shares of StockMarketBeat

MarketAxess Holdings Inc. (NASDAQ:MKTX - Get Free Report) General Counsel Scott Pintoff sold 100 shares of the stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $116.03, for a total transaction of $11,603.00. Following the transaction, the general counsel owned 11,786 shares in the company, valued at approximately $1,367,529.58. The trade was a 0.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

NASDAQ:MKTX

Read Insider Selling: MarketAxess (NASDAQ:MKTX) General Counsel Sells 100 Shares of Stock

Trending News All MarketBeat Instant News Alerts Sort By

Time Frame

Alert Type

Keywords

Page 1 of 327

Get 30 Days of MarketBeat All Access for Free

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.

Start Your 30-Day Trial

Sign in to your free account to enjoy these benefits

In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer.

Quarterly financial reports play a vital role on Wall Street, as they help investors see how a company has performed and what might be coming down the road in the near-term. And out of all of the metrics and results to consider, earnings is one of the most important.

The earnings figure itself is key, of course, but a beat or miss on the bottom line can sometimes be just as, if not more, important. Therefore, investors should consider paying close attention to these earnings surprises, as a big beat can help a stock climb and vice versa.

Hunting for 'earnings whispers' or companies poised to beat their quarterly earnings estimates is a somewhat common practice. But that doesn't make it easy. One way that has been proven to work is by using the Zacks Earnings ESP tool.

The Zacks Earnings ESP, ExplainedThe Zacks Expected Surprise Prediction, or ESP, works by locking in on the most up-to-date analyst earnings revisions because they can be more accurate than estimates from weeks or even months before the actual release date. The thinking is pretty straightforward: analysts who provide earnings estimates closer to the report are likely to have more information.

Now that we understand the basic idea, let's look at how the Expected Surprise Prediction works. The ESP is calculated by comparing the Most Accurate Estimate to the Zacks Consensus Estimate, with the percentage difference between the two giving us the Zacks ESP figure.

When we join a positive earnings ESP with a Zacks Rank #3 (Hold) or stronger, stocks posted a positive bottom-line surprise 70% of the time. Plus, this system saw investors produce roughly 28% annual returns on average, according to our 10 year backtest.

Stocks with a #3 (Hold) ranking, which is most stocks covered at 60%, are expected to perform in-line with the broader market. But stocks that fall into the #2 (Buy) and #1 (Strong Buy) ranking, or the top 15% and top 5% of stocks, respectively, should outperform the market. Strong Buy stocks should outperform more than any other rank.

Should You Consider Bank of Montreal?The last thing we will do today, now that we have a grasp on the ESP and how powerful of a tool it can be, is to quickly look at a qualifying stock. Bank of Montreal (BMO - Free Report) holds a #3 (Hold) at the moment and its Most Accurate Estimate comes in at $2.47 a share 13 days away from its upcoming earnings release on May 27, 2026.

Bank of Montreal's Earnings ESP sits at +1.51%, which, as explained above, is calculated by taking the percentage difference between the $2.47 Most Accurate Estimate and the Zacks Consensus Estimate of $2.43. BMO is also part of a large group of stocks that boast a positive ESP. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

BMO is part of a big group of Finance stocks that boast a positive ESP, and investors may want to take a look at MetLife (MET - Free Report) as well.

Slated to report earnings on August 5, 2026, MetLife holds a #3 (Hold) ranking on the Zacks Rank, and its Most Accurate Estimate is $2.46 a share 83 days from its next quarterly update.

For MetLife, the percentage difference between its Most Accurate Estimate and its Zacks Consensus Estimate of $2.45 is +0.11%.

Because both stocks hold a positive Earnings ESP, BMO and MET could potentially post earnings beats in their next reports.

Find Stocks to Buy or Sell Before They're ReportedUse the Zacks Earnings ESP Filter to turn up stocks with the highest probability of positively, or negatively, surprising to buy or sell before they're reported for profitable earnings season trading. Check it out here >>

MetLife delivers robust adjusted income, supporting a bullish stance on common shares and fixed-rate preferreds. MET's preferred dividend payout ratio remains low, with $24.5B in common equity providing strong downside protection for preferred holders. Series A floating-rate preferreds yield 5.45%-5.5%, attractive if short-term rates rise, but fixed-rate Series F offers a higher current yield.

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancerPR Newswire

CHICAGO, May 29, 2026

Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson's RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated diseaseConsistent responses observed across atypical EGFR mutation subgroups, including those historically associated with poorer outcomesASCO 2026 results reinforce the significance of RYBREVANT®-based regimens for patients across EGFR mutations, /PRNewswire/ -- Johnson & Johnson NYSE:JNJ today announced updated results from the Phase 1/1b CHRYSALIS-2 study evaluating intravenous RYBREVANT® (amivantamab-vmjw) in combination with LAZCLUZE® (lazertinib) in patients with advanced non-small cell lung cancer (NSCLC) with atypical epidermal growth factor receptor (EGFR) mutations. The analysis showed encouraging long-term outcomes with RYBREVANT® plus LAZCLUZE® in this difficult-to-treat population. Median overall survival, a secondary endpoint, was nearly 3.5 years.1 The primary endpoint of objective response rate was previously reported.2 These results add to the growing body of evidence demonstrating the potential of RYBREVANT® plus LAZCLUZE® to deliver durable survival outcomes across both common and atypical EGFR-mutated advanced NSCLC in the first-line setting. Data were presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #8501).1

Significant unmet need in patients with atypical EGFR-mutated NSCLCPatients with atypical EGFR-mutated NSCLC tend to have poorer outcomes than those with common EGFR mutations (exon 19 deletions and L858R substitutions), and effective first-line treatment options remain limited.3,4 These mutations represent approximately 10-20 percent of all EGFR-mutated cases.5 Median overall survival with current standard of care single-agent therapies remains under two years, highlighting a significant unmet need for treatments that can deliver more durable benefit in this setting.6,7 RYBREVANT® is designed to dual target EGFR and mesenchymal-epithelial transition (MET), while engaging the immune system.8,9,10,11 These complementary mechanisms play a central role in tumor growth and treatment resistance and may help address the underlying drivers of disease.Expert and company perspectives supporting the strength of RYBREVANT® plus LAZCLUZE®"For patients with non-small cell lung cancer harboring atypical EGFR-mutations, first-line treatment decisions are often clouded by uncertainty regarding the efficacy of currently available EGFR tyrosine kinase inhibitors," said Joel Neal,* M.D., Ph.D., principal investigator of the Phase 1/1b CHRYSALIS-2 study. "The responses we've seen in this trial suggest the potential for more durable disease control, and the overall survival data reinforce that picture. These long-term outcomes begin to change how we think about treatment options in managing this subtype of lung cancer." Neal is also a Professor of Medicine in the Division of Oncology at Stanford Medicine."Disease progression and molecular resistance remain critical barriers in EGFR-mutated non-small cell lung cancer," said Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson. "RYBREVANT-based combinations demonstrate the power of changing the biology by addressing multiple disease drivers from the start rather than relying on single-pathway strategies. With strong outcomes across all known EGFR mutations, this approach is raising the bar for what first-line treatment can achieve."Detailed CHRYSALIS-2 study resultsIn Cohort C of the CHRYSALIS-2 study, RYBREVANT® plus LAZCLUZE® was evaluated as a first-line treatment in patients with atypical EGFR-mutated advanced NSCLC, excluding EGFR exon 20 insertion mutations (n=49). The most common atypical EGFR mutations included G719X (55 percent), S768X (27 percent) and L861X (24 percent), with 35 percent of patients harboring multiple atypical mutations. The study previously reported an objective response rate of 57 percent (primary endpoint).1,2Median overall survival with RYBREVANT® plus LAZCLUZE® reached nearly 3.5 years (41.0 months; 95 percent confidence interval [CI], 27.7-not estimable) at a median follow-up of 31.3 months. Overall survival rates were 55 percent at three years and 46 percent at four years.1Consistent clinical activity was observed across atypical EGFR mutation subgroups, as well as across patient and disease characteristics such as central nervous system metastases and TP53 status. Patients were also able to remain on treatment long-term across mutation groups and baseline characteristics. Notably, 41 percent of patients remained on RYBREVANT® for two years or longer, further supporting the durable survival observed with this combination.1The safety profile of RYBREVANT® plus LAZCLUZE® was consistent with previous reports, with no new safety signals observed with longer follow-up. Most adverse events were Grade 1 or 2. The most common treatment-emergent adverse events occurring in more than 30 percent of patients included paronychia (78 percent), rash (65 percent), hypoalbuminemia (61 percent) and infusion-related reactions (61 percent).1RYBREVANT®-based regimens are approved for patients with EGFR-mutated advanced NSCLC across common (exon 19 deletions and exon 21 L858R substitution mutations) and exon 20 insertion mutations, including in the first-line setting.12 These results further define long-term outcomes with first-line RYBREVANT® plus LAZCLUZE® for patients with atypical EGFR mutations. Additional data being presented at ASCO 2026 in lung, head and neck, and colorectal cancers underscore the broader potential of RYBREVANT® across tumor types.About the CHRYSALIS-2 StudyCHRYSALIS-2 (NCT04077463) is an open-label Phase 1/1b study to evaluate the safety and pharmacokinetics of LAZCLUZE®, a third-generation EGFR-TKI, as monotherapy or in combinations with RYBREVANT®, a human bispecific EGFR and cMet antibody in participants with advanced NSCLC. The study enrolled 460 patients with advanced NSCLC.13Cohort C of the ongoing CHRYSALIS-2 study evaluates patients with atypical EGFR-mutated advanced NSCLC, excluding exon 20 insertion and classical EGFR mutations, who are treatment-naïve or have received up to two prior lines of therapy. Patients received intravenous RYBREVANT® in combination with LAZCLUZE® administered orally once daily.13About Non-Small Cell Lung Cancer Worldwide, lung cancer is one of the most common cancers, with NSCLC making up 80 to 85 percent of all lung cancer cases.14,15 The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.16 Among the most common driver mutations in NSCLC are alterations in EGFR, which is a receptor tyrosine kinase controlling cell growth and division.17 EGFR mutations are present in 10 to 15 percent of Western patients with NSCLC with adenocarcinoma histology and occur in 40 to 50 percent of Asian patients.14,15,18,19,20,21 EGFR ex19del or EGFR L858R mutations are the most common EGFR mutations.22 The five-year survival rate for all people with advanced NSCLC and EGFR mutations treated with EGFR tyrosine kinase inhibitors (TKIs) is less than 20 percent.23,24 EGFR exon 20 insertion mutations are the third-most prevalent activating EGFR mutation.25 Patients with EGFR exon 20 insertion mutations have a real-world five-year overall survival (OS) of eight percent in the frontline setting, which is worse than patients with EGFR ex19del or L858R mutations, who have a real-world five-year OS of 19 percent.26About RYBREVANT®RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) received U.S. FDA approval in December 2025 and is approved in multiple markets worldwide for the treatment of adults with EGFR-mutated non-small cell lung cancer (NSCLC), including those with exon 19 deletions, exon 21 L858R substitution mutations, and exon 20 insertion mutations. It is the only subcutaneous therapy approved in these populations and can be used as monotherapy or in combination with LAZCLUZE® (lazertinib) or chemotherapy in the front- and second-line settings, offering convenient monthly† or bi-weekly dosing. RYBREVANT FASPRO™ is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme's ENHANZE® drug delivery technology.RYBREVANT® (amivantamab-vmjw), administered intravenously, received U.S. FDA approval in March 2024 and is approved for the same indications as RYBREVANT FASPRO™ across multiple markets. RYBERVANT® is a first-in-class, fully human bispecific antibody targeting EGFR and MET, designed to inhibit tumor growth while engaging the immune system.The effectiveness of RYBREVANT FASPRO™ is supported by the established clinical profile of RYBREVANT®, including data from multiple Phase 3 studies such as MARIPOSA, which demonstrated improvements in progression-free and overall survival when used in combination with LAZCLUZE® in first-line advanced EGFR-mutated NSCLC.The National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®)‡ 27 include amivantamab-vmjw (RYBREVANT®) across its FDA-approved treatment settings, including as a Category 1 preferred option in combination with lazertinib (LAZCLUZE®) for first-line treatment of patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations. Subcutaneous amivantamab and hyaluronidase-lpuj (RYBREVANT FASPRO™) may be substituted for IV amivantamab-vmjw (RYBREVANT®) where appropriate. See the latest NCCN Guidelines® for NSCLC for complete information.§ ||The NCCN Guidelines for Central Nervous System Cancers also include amivantamab (RYBREVANT®)-based regimens, including in combination with lazertinib (LAZCLUZE®), as the only NCCN-preferred combination options for patients with EGFR-mutated NSCLC and brain metastases.§ ||Beyond NSCLC, RYBREVANT-based therapies are being investigated across other solid tumors, including head and neck and colorectal cancers.The legal manufacturer for RYBREVANT® is Janssen Biotech, Inc. For more information, visit www.rybrevanthcp.com.About LAZCLUZE®In 2018, Janssen Biotech, Inc., entered into a license and collaboration agreement with Yuhan Corporation for the development of LAZCLUZE® (marketed as LECLAZA in South Korea). LAZCLUZE® is an oral, third-generation, brain-penetrant EGFR TKI that targets both the T790M mutation and activating EGFR mutations while sparing wild-type EGFR. An analysis of the efficacy and safety of LAZCLUZE® from the Phase 3 LASER301 study was published in The Journal of Clinical Oncology in 2023.28The legal manufacturer for LAZCLUZE® is Janssen Biotech, Inc. and Yuhan Corporation.INDICATIONSRYBREVANT® (amivantamab-vmjw) is indicated:

in combination with LAZCLUZE® (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test.as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA approved test, whose disease has progressed on or after platinum-based chemotherapy.IMPORTANT SAFETY INFORMATION FOR RYBREVANT FASPRO™ AND RYBREVANT® 12,29CONTRAINDICATIONSRYBREVANT FASPRO™ is contraindicated in patients with known hypersensitivity to hyaluronidase or to any of its excipients.WARNINGS AND PRECAUTIONS Hypersensitivity and Administration-Related Reactions with RYBREVANT FASPRO™ RYBREVANT FASPRO™ can cause hypersensitivity and administration-related reactions (ARR); signs and symptoms of ARR include dyspnea, flushing, fever, chills, chest discomfort, hypotension, and vomiting. The median time to ARR onset is approximately 2 hours.

RYBREVANT FASPRO™ with LAZCLUZE®

In PALOMA-3 (n=206), all Grade ARR occurred in 13% of patients, including 0.5% Grade 3. Of the patients who experienced ARR, 89% occurred with the initial dose (Week 1, Day 1).

Premedicate with antihistamines, antipyretics, and glucocorticoids and administer RYBREVANT FASPRO™ as recommended. Monitor patients for any signs and symptoms of administration-related reactions during injection in a setting where cardiopulmonary resuscitation medication and equipment are available. Interrupt RYBREVANT FASPRO™ injection if ARR is suspected. Resume treatment upon resolution of symptoms or permanently discontinue RYBREVANT FASPRO™ based on severity.Infusion-Related Reactions with RYBREVANT®RYBREVANT® can cause infusion-related reactions (IRR) including anaphylaxis; signs and symptoms of IRR include dyspnea, flushing, fever, chills, nausea, chest discomfort, hypotension, and vomiting. The median time to IRR onset is approximately 1 hour.

RYBREVANT® with LAZCLUZE®

In MARIPOSA (n=421), IRRs occurred in 63% of patients, including Grade 3 in 5% and Grade 4 in 1% of patients. IRR-related infusion modifications occurred in 54%, dose reduction in 0.7%, and permanent discontinuation of RYBREVANT® in 4.5% of patients.

RYBREVANT® with Carboplatin and Pemetrexed

Based on the pooled safety population (n=281), IRRs occurred in 50% of patients including Grade 3 (3.2%) adverse reactions. IRR-related infusion modifications occurred in 46%, and permanent discontinuation of RYBREVANT® in 2.8% of patients.

RYBREVANT® as a Single Agent

In CHRYSALIS (n=302), IRRs occurred in 66% of patients. IRRs occurred in 65% of patients on Week 1 Day 1, 3.4% on Day 2 infusion, 0.4% with Week 2 infusion, and were cumulatively 1.1% with subsequent infusions. 97% were Grade 1-2, 2.2% were Grade 3, and 0.4% were Grade 4. The median time to onset was 1 hour (range: 0.1 to 18 hours) after start of infusion. IRR-related infusion modifications occurred in 62%, and permanent discontinuation of RYBREVANT® in 1.3% of patients.Premedicate with antihistamines, antipyretics, and glucocorticoids and infuse RYBREVANT® as recommended. Administer RYBREVANT® via a peripheral line on Week 1 and Week 2 to reduce the risk of IRRs. Monitor patients for signs and symptoms of IRRs in a setting where cardiopulmonary resuscitation medication and equipment are available. Interrupt infusion if IRR is suspected. Reduce the infusion rate or permanently discontinue RYBREVANT® based on severity. If an anaphylactic reaction occurs, permanently discontinue RYBREVANT®.Interstitial Lung Disease/Pneumonitis RYBREVANT FASPRO™ and RYBREVANT® can cause severe and fatal interstitial lung disease (ILD)/pneumonitis.

RYBREVANT FASPRO™ with LAZCLUZE®

In PALOMA-3, ILD/pneumonitis occurred in 6% of patients, including Grade 3 in 1%, Grade 4 in 1.5%, and fatal cases in 1.9% of patients. 5% of patients permanently discontinued RYBREVANT FASPRO™ and LAZCLUZE® due to ILD/pneumonitis.

RYBREVANT® with LAZCLUZE®

In MARIPOSA, ILD/pneumonitis occurred in 3.1% of patients, including Grade 3 in 1.0% and Grade 4 in 0.2% of patients. There was one fatal case of ILD/pneumonitis and 2.9% of patients permanently discontinued RYBREVANT® and LAZCLUZE® due to ILD/pneumonitis.

RYBREVANT® with Carboplatin and Pemetrexed

Based on the pooled safety population, ILD/pneumonitis occurred in 2.1% of patients with 1.8% of patients experiencing Grade 3 ILD/pneumonitis. 2.1% discontinued RYBREVANT® due to ILD/pneumonitis.

RYBREVANT® as a Single Agent

In CHRYSALIS, ILD/pneumonitis occurred in 3.3% of patients, with 0.7% of patients experiencing Grade 3 ILD/pneumonitis. Three patients (1%) permanently discontinued RYBREVANT® due to ILD/pneumonitis.Monitor patients for new or worsening symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, fever). Immediately withhold RYBREVANT FASPRO™ or RYBREVANT® and LAZCLUZE® (when applicable) in patients with suspected ILD/pneumonitis and permanently discontinue if ILD/pneumonitis is confirmed.Venous Thromboembolic (VTE) Events with Concomitant Use with LAZCLUZE®RYBREVANT FASPRO™ and RYBREVANT® in combination with LAZCLUZE® can cause serious and fatal venous thromboembolic (VTE) events, including deep vein thrombosis and pulmonary embolism. Without prophylactic anticoagulation, the majority of these events occurred during the first four months of treatment.

RYBREVANT FASPRO™ with LAZCLUZE®

In PALOMA-3 (n=206), all Grade VTE occurred in 11% of patients and 1.5% were Grade 3. 80% (n=164) of patients received prophylactic anticoagulation at study entry, with an all Grade VTE incidence of 7%. In patients who did not receive prophylactic anticoagulation (n=42), all Grade VTE occurred in 17% of patients. In total, 0.5% of patients had VTE leading to dose reductions of RYBREVANT FASPRO™ and no patients required permanent discontinuation. The median time to onset of VTEs was 95 days (range: 17 to 390).

RYBREVANT® with LAZCLUZE®

In MARIPOSA (n=421), VTEs occurred in 36% of patients including Grade 3 in 10% and Grade 4 in 0.5% of patients. On-study VTEs occurred in 1.2% of patients (n=5) while receiving anticoagulation therapy. There were two fatal cases of VTE (0.5%), 9% of patients had VTE leading to dose interruptions of RYBREVANT®, and 7% of patients had VTE leading to dose interruptions of LAZCLUZE®; 1% of patients had VTE leading to dose reductions of RYBREVANT®, and 0.5% of patients had VTE leading to dose reductions of LAZCLUZE®; 3.1% of patients had VTE leading to permanent discontinuation of RYBREVANT®, and 1.9% of patients had VTE leading to permanent discontinuation of LAZCLUZE®. The median time to onset of VTEs was 84 days (range: 6 to 777).Administer prophylactic anticoagulation for the first four months of treatment. The use of Vitamin K antagonists is not recommended.Monitor for signs and symptoms of VTE events and treat as medically appropriate. Withhold RYBREVANT FASPRO™ or RYBREVANT® and LAZCLUZE® based on severity. Once anticoagulant treatment has been initiated, resume RYBREVANT FASPRO™ or RYBREVANT® and LAZCLUZE® at the same dose level at the discretion of the healthcare provider. In the event of VTE recurrence despite therapeutic anticoagulation, permanently discontinue RYBREVANT FASPRO™ or RYBREVANT®. Treatment can continue with LAZCLUZE® at the same dose level at the discretion of the healthcare provider. Refer to the LAZCLUZE® Prescribing Information for recommended LAZCLUZE® dosage modification.Dermatologic Adverse ReactionsRYBREVANT FASPRO™ and RYBREVANT® can cause severe rash including toxic epidermal necrolysis (TEN), dermatitis acneiform, pruritus and dry skin.

RYBREVANT FASPRO™ with LAZCLUZE®

In PALOMA-3, rash occurred in 80% of patients, including Grade 3 in 17% and Grade 4 in 0.5% of patients. Rash leading to dose reduction occurred in 11% of patients, and RYBREVANT FASPRO™ was permanently discontinued due to rash in 1.5% of patients.

RYBREVANT® with LAZCLUZE®

In MARIPOSA, rash occurred in 86% of patients, including Grade 3 in 26% of patients. The median time to onset of rash was 14 days (range: 1 to 556 days). Rash leading to dose interruptions occurred in 37% of patients for RYBREVANT® and 30% for LAZCLUZE®, rash leading to dose reductions occurred in 23% of patients for RYBREVANT® and 19% for LAZCLUZE®, and rash leading to permanent discontinuation occurred in 5% of patients for RYBREVANT® and 1.7% for LAZCLUZE®.

RYBREVANT® with Carboplatin and Pemetrexed

Based on the pooled safety population, rash occurred in 82% of patients, including Grade 3 (15%) adverse reactions. Rash leading to dose reductions occurred in 14% of patients, and 2.5% permanently discontinued RYBREVANT® and 3.1% discontinued pemetrexed.

RYBREVANT® as a Single Agent

In CHRYSALIS, rash occurred in 74% of patients, including Grade 3 in 3.3% of patients. The median time to onset of rash was 14 days (range: 1 to 276 days). Rash leading to dose reduction occurred in 5% and permanent discontinuation due to rash occurred in 0.7% of patients. Toxic epidermal necrolysis occurred in one patient (0.3%).When initiating treatment with RYBREVANT FASPRO or RYBREVANT and LAZCLUZE, prophylactic and concomitant medications are recommended to reduce the risk and severity of dermatologic adverse reactions. Instruct patients to limit sun exposure during and for 2 months after treatment. Advise patients to wear protective clothing and use broad spectrum UVA/UVB sunscreen.If skin reactions develop, administer supportive care including topical corticosteroids and topical and/or oral antibiotics. For Grade 3 reactions, add oral steroids and consider dermatologic consultation. Promptly refer patients presenting with severe rash, atypical appearance or distribution, or lack of improvement within 2 weeks to a dermatologist. For patients receiving RYBREVANT FASPRO™ or RYBREVANT® in combination with LAZCLUZE®, withhold, reduce the dose, or permanently discontinue both drugs based on severity. For patients receiving RYBREVANT FASPRO™ or RYBREVANT® as a single agent or in combination with carboplatin and pemetrexed, withhold, dose reduce or permanently discontinue RYBREVANT FASPRO™ or RYBREVANT® based on severityHepatotoxicityLAZCLUZE® in combination with amivantamab can cause severe hepatotoxicity (including increased ALT and AST).

RYBREVANT® with LAZCLUZE®

In MARIPOSA, based on adverse reaction data, hepatotoxicity occurred in 49% of patients treated with LAZCLUZE®, including Grade 3 in 9.3% of patients and Grade 4 in 0.5%. LAZCLUZE® was interrupted for an adverse reaction of hepatotoxicity in 8% of patients, the dose was reduced in 1.4% and permanently discontinued in 0.2%.Perform liver function tests (including ALT, AST, and total bilirubin) before initiation of LAZCLUZE® and during treatment, as clinically indicated. Withhold, reduce the dose, or permanently discontinue LAZCLUZE® and amivantamab based on severity.Ocular ToxicityRYBREVANT FASPRO™ and RYBREVANT® can cause ocular toxicity including keratitis, blepharitis, dry eye symptoms, conjunctival redness, blurred vision, visual impairment, ocular itching, eye pruritus and uveitis.

RYBREVANT FASPRO™ with LAZCLUZE®

In PALOMA-3, all Grade ocular toxicity occurred in 13% of patients, including 0.5% Grade 3.

RYBREVANT® with LAZCLUZE®

In MARIPOSA, ocular toxicity occurred in 16%, including Grade 3 or 4 ocular toxicity in 0.7% of patients.

RYBREVANT® with Carboplatin and Pemetrexed

Based on the pooled safety population, ocular toxicity occurred in 16% of patients. All events were Grade 1 or 2.

RYBREVANT® as a Single Agent

In CHRYSALIS, keratitis occurred in 0.7% and uveitis occurred in 0.3% of patients. All events were Grade 1-2.Promptly refer patients presenting with new or worsening eye symptoms to an ophthalmologist. Withhold, dose reduce or permanently discontinue RYBREVANT FASPRO™ or RYBREVANT® and continue LAZCLUZE® based on severity.Embryo-Fetal ToxicityBased on animal models, RYBREVANT FASPRO™, RYBREVANT® and LAZCLUZE® can cause fetal harm when administered to a pregnant woman. Verify pregnancy status of females of reproductive potential prior to initiating RYBREVANT FASPRO™ and RYBREVANT®. Advise pregnant women and females of reproductive potential of the potential risk to the fetus. Advise patients of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of RYBREVANT FASPRO™ or RYBREVANT®, and for 3 weeks after the last dose of LAZCLUZE®.ADVERSE REACTIONSRYBREVANT FASPRO™ with LAZCLUZE®In PALOMA-3 (n=206), the most common adverse reactions (≥20%) were rash (80%), nail toxicity (58%), musculoskeletal pain (50%), fatigue (37%), stomatitis (36%), edema (34%), nausea (30%), diarrhea (22%), vomiting (22%), constipation (22%), decreased appetite (22%), and headache (21%). The most common Grade 3 or 4 laboratory abnormalities (≥2%) were decreased lymphocyte count (6%), decreased sodium (5%), decreased potassium (5%), decreased albumin (4.9%), increased alanine aminotransferase (3.4%), decreased platelet count (2.4%), increased aspartate aminotransferase (2%), increased gammaglutamyl transferase (2%), and decreased hemoglobin (2%).Serious adverse reactions occurred in 33% of patients, with those occurring in ≥2% of patients including ILD/pneumonitis (6%); and pneumonia, VTE and fatigue (2.4% each). Death due to adverse reactions occurred in 5% of patients treated with RYBREVANT FASPRO™, including ILD/pneumonitis (1.9%), pneumonia (1.5%), and respiratory failure and sudden death (1% each).RYBREVANT® with LAZCLUZE®In MARIPOSA (n=421), the most common adverse reactions (ARs) (≥20%) were rash (86%), nail toxicity (71%), infusion-related reactions (IRRs) (RYBREVANT®) (63%), musculoskeletal pain (47%), stomatitis (43%), edema (43%), VTE (36%), paresthesia (35%), fatigue (32%), diarrhea (31%), constipation (29%), COVID-19 (26%), hemorrhage (25%), dry skin (25%), decreased appetite (24%), pruritus (24%), and nausea (21%). The most common Grade 3 or 4 laboratory abnormalities (≥2%) were decreased albumin (8%), decreased sodium (7%), increased ALT (7%), decreased potassium (5%), decreased hemoglobin (3.8%), increased AST (3.8%), increased GGT (2.6%), and increased magnesium (2.6%).Serious ARs occurred in 49% of patients, with those occurring in ≥2% of patients including VTE (11%), pneumonia (4%), ILD/pneumonitis and rash (2.9% each), COVID-19 (2.4%), and pleural effusion and IRRs (RYBREVANT®) (2.1% each). Fatal ARs occurred in 7% of patients due to death not otherwise specified (1.2%); sepsis and respiratory failure (1% each); pneumonia, myocardial infarction, and sudden death (0.7% each); cerebral infarction, pulmonary embolism (PE), and COVID-19 infection (0.5% each); and ILD/pneumonitis, acute respiratory distress syndrome (ARDS), and cardiopulmonary arrest (0.2% each).RYBREVANT® with Carboplatin and PemetrexedIn MARIPOSA-2 (n=130), the most common ARs (≥20%) were rash (72%), IRRs (59%), fatigue (51%), nail toxicity (45%), nausea (45%), constipation (39%), edema (36%), stomatitis (35%), decreased appetite (31%), musculoskeletal pain (30%), vomiting (25%), and COVID-19 (21%). The most common Grade 3 to 4 laboratory abnormalities (≥2%) were decreased neutrophils (49%), decreased white blood cells (42%), decreased lymphocytes (28%), decreased platelets (17%), decreased hemoglobin (12%), decreased potassium (11%), decreased sodium (11%), increased alanine aminotransferase (3.9%), decreased albumin (3.8%), and increased gamma-glutamyl transferase (3.1%).In MARIPOSA-2, serious ARs occurred in 32% of patients, with those occurring in >2% of patients including dyspnea (3.1%), thrombocytopenia (3.1%), sepsis (2.3%), and PE (2.3%). Fatal ARs occurred in 2.3% of patients; these included respiratory failure, sepsis, and ventricular fibrillation (0.8% each).In PAPILLON (n=151), the most common ARs (≥20%) were rash (90%), nail toxicity (62%), stomatitis (43%), IRRs (42%), fatigue (42%), edema (40%), constipation (40%), decreased appetite (36%), nausea (36%), COVID-19 (24%), diarrhea (21%), and vomiting (21%). The most common Grade 3 to 4 laboratory abnormalities (≥2%) were decreased albumin (7%), increased alanine aminotransferase (4%), increased gamma-glutamyl transferase (4%), decreased sodium (7%), decreased potassium (11%), decreased magnesium (2%), and decreases in white blood cells (17%), hemoglobin (11%), neutrophils (36%), platelets (10%), and lymphocytes (11%).In PAPILLON, serious ARs occurred in 37% of patients, with those occurring in ≥2% of patients including rash, pneumonia, ILD, PE, vomiting, and COVID-19. Fatal adverse reactions occurred in 7 patients (4.6%) due to pneumonia, cerebrovascular accident, cardio-respiratory arrest, COVID-19, sepsis, and death not otherwise specified.RYBREVANT® as a Single AgentIn CHRYSALIS (n=129), the most common ARs (≥20%) were rash (84%), IRR (64%), paronychia (50%), musculoskeletal pain (47%), dyspnea (37%), nausea (36%), fatigue (33%), edema (27%), stomatitis (26%), cough (25%), constipation (23%), and vomiting (22%). The most common Grade 3 to 4 laboratory abnormalities (≥2%) were decreased lymphocytes (8%), decreased albumin (8%), decreased phosphate (8%), decreased potassium (6%), increased alkaline phosphatase (4.8%), increased glucose (4%), increased gamma-glutamyl transferase (4%), and decreased sodium (4%).Serious ARs occurred in 30% of patients, with those occurring in ≥2% of patients including PE, pneumonitis/ILD, dyspnea, musculoskeletal pain, pneumonia, and muscular weakness. Fatal adverse reactions occurred in 2 patients (1.5%) due to pneumonia and 1 patient (0.8%) due to sudden death.LAZCLUZE® DRUG INTERACTIONSAvoid concomitant use of LAZCLUZE® with strong and moderate CYP3A4 inducers. Consider an alternate concomitant medication with no potential to induce CYP3A4.Monitor for adverse reactions associated with a CYP3A4 or BCRP substrate where minimal concentration changes may lead to serious adverse reactions, as recommended in the approved product labeling for the CYP3A4 or BCRP substrate.Please see full Prescribing Information for RYBREVANT FASPRO™, RYBREVANT® and LAZCLUZE®.cp-491009v2About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com. Follow us at @JNJInnovMed.Cautions Concerning Forward-Looking StatementsThis press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of RYBREVANT®-based regimens. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com, or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

###* Joel W. Neal, M.D., Ph.D., has served as a consultant to Johnson & Johnson; he has not been paid for any media work.† Once monthly after weekly injections from weeks 1-4.‡ The NCCN content does not constitute medical advice and should not be used in place of seeking professional medical advice, diagnosis or treatment by licensed practitioners. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.§ See the NCCN Guidelines for detailed recommendations, including other treatment options.|| The NCCN Guidelines for NSCLC provide recommendations for certain individual biomarkers that should be tested and recommend testing techniques but do not endorse any specific commercially available biomarker assays or commercial laboratories.Source: Johnson & Johnson1 Neal JW, et al. Overall survival of first-line amivantamab plus lazertinib in atypical EGFR-mutated advanced NSCLC: Updated results from the CHRYSALIS-2 study. Presented at: 2026 ASCO Annual Meeting; 2026; Chicago, IL.
2 Tomasini P, Wang Y, Li Y, et al. Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2. J Clin Oncol. 2026;44(1):54-65. doi:10.1200/JCO-24-02835
3 Kim EY, Cho EN, Park HS, et al. Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma. Cancer Biol Ther. 2016;17(3):237-245. doi:10.1080/15384047.2016.1139235
4 Patil T, Mushtaq R, Marsh S, et al. Clinicopathologic characteristics, treatment outcomes, and acquired resistance patterns of atypical EGFR mutations and HER2 alterations in stage IV non-small-cell lung cancer. Clin Lung Cancer. 2020;21(3):e191-e204. doi:10.1016/j.cllc.2019.11.008
5 Fabrizio FP, Attili I, de Marinis F. Uncommon and Rare EGFR Mutations in Non-Small Cell Lung Cancer Patients with a Focus on Exon 20 Insertions and the Phase 3 PAPILLON Trial: The State of the Art. Cancers. 2024; 16(7):1331. https://doi.org/10.3390/cancers16071331
6 Yang JC, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015;16(7):830-838. doi:10.1016/S1470-2045(15)00026-1
7 GILOTRIF® (afatinib tablets), for oral use [package insert]. Boehringer Ingelheim Pharmaceuticals, Inc.; 2022.
8 Moores SL, Chiu ML, Bushey BS, et al. A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors. Cancer Res. 2016;76(13):3942-3953. doi:10.1158/0008-5472.CAN-15-2833
9 Vijayaraghavan S, Lipfert L, Chevalier K, et al. Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis. Mol Cancer Ther. 2020;19(10):2044-2056. doi:10.1158/1535-7163.MCT-20-0071
10 Yun J, Lee SH, Kim SY, et al. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020;10(8):1194-1209. doi:10.1158/2159-8290.CD-20-0116
11 Asia-Pacific practical consensus in the management of adverse events related to amivantamab-based therapies in non-small cell lung cancer. Lung Cancer. Published online May 22, 2026. doi:10.1016/S0169-5002(26)00466-6.
12 RYBREVANT® Prescribing Information. Horsham, PA: Janssen Biotech, Inc.
13 ClinicalTrials.gov. A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (CHRYSALIS-2). Available at: https://clinicaltrials.gov/ct2/show/NCT04077463. Accessed May 2026.
14 The World Health Organization. Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed May 2026.
15 American Cancer Society. What is Lung Cancer? https://www.cancer.org/content/cancer/en/cancer/lung-cancer/about/what-is.html. Accessed May 2026.
16 Oxnard JR, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013 Feb;8(2):179-84. doi: 10.1097/JTO.0b013e3182779d18.
17 Bauml JM, et al. Underdiagnosis of EGFR Exon 20 Insertion Mutation Variants: Estimates from NGS-based Real World Datasets. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.
18 Pennell NA, et al. A phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small cell lung cancer. J Clin Oncol. 37:97-104.
19 Burnett H, et al. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.
20 Zhang YL, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985-78993.
21 Midha A, et al. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity. Am J Cancer Res. 2015;5(9):2892-2911.
22 American Lung Association. EGFR and Lung Cancer. https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/symptoms-diagnosis/biomarker-testing/egfr. Accessed May 2026.
23 Howlader N, et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission, posted to the SEER web site.
24 Lin JJ, et al. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J Thorac Oncol. 2016 Apr;11(4):556-65.
25 Arcila, M. et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013 Feb; 12(2):220-9.
26 Girard N, et al. Comparative clinical outcomes for patients with NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.
27 Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.3.2026 © National Comprehensive Cancer Network, Inc. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org. Accessed May 2026.
28 Cho BC, et al. Lazertinib versus gefitinib as first-line treatment in patients with EGFR-mutated advanced non-small-cell lung cancer: Results From LASER301. J Clin Oncol. 2023;41(26):4208-4217.
29 LAZCLUZE® Prescribing Information. Horsham, PA: Janssen Biotech, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-demonstrates-prolonged-clinical-benefit-as-a-first-line-treatment-for-atypical-egfr-mutated-non-small-cell-lung-cancer-302785924.htmlSOURCE Johnson & Johnson

NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) today announced that John McCallion, executive vice president and CFO, and head of MetLife Investment Management, will participate in a fireside chat at the Morgan Stanley US Financials Conference on Wednesday, June 10, 2026, at 1:00 pm ET.

The live webcast can be listened to by clicking here. Please visit the link at least 15 minutes in advance to allow time to register or sign in.

If you miss the remarks, you can access a replay at the above link, which will be available until June 17, 2026 at 11:59 pm ET.

About MetLife

MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates (“MetLife”), is one of the world’s leading financial services companies, providing insurance, annuities, employee benefits and asset management to help individual and institutional customers build a more confident future. Founded in 1868, MetLife has operations in more than 40 markets globally and holds leading positions in the United States, Asia, Latin America, Europe and the Middle East. For more information, visit www.metlife.com.

More News From MetLife, Inc.

MetLife delivers strong Q1 2026 results with adjusted EPS up 23% to $2.42 and ROE at 17%, highlighting robust core performance. I find MET's fixed-income preferreds, especially Series F, compelling with yields near 6.5% and payout ratios under 4%, offering rare quality and safety. Common shares trade at a fair 8.5x forward P/E with limited near-term upside; total equity returns approximate 8% annually via buybacks and dividends.

-

NEW YORK--(BUSINESS WIRE)--MetLife today announced the Non-Qualified Assignment Flex Agreement (NQA-FA), a new deferred payment solution designed to help attorneys and brokers resolve non-physical injury claims with more flexible settlement structures. The NQA-FA enables settlements to be paid over time, including through deferred start dates, lump sums and customized payment schedules aligned to client needs.

MetLife today announced the Non-Qualified Assignment Flex Agreement (NQA-FA), a new deferred payment solution designed to help attorneys and brokers resolve non-physical injury claims with more flexible settlement structures.

Share The NQA-FA utilizes a funding agreement rather than an annuity and gives attorneys and brokers greater control over how and when settlement payments are delivered across a broad range of non-physical injury cases. These include employment litigation, wrongful termination, discrimination, contract disputes, construction defects, property and environmental claims, liability policy buy-outs, punitive damages, and attorney fees. With approval, both individuals and businesses may be designated as payees.

Only a small percentage of employment litigation cases go to trial, with most resolved through a settlement. In fiscal year 2025, 88,201 workplace discrimination charges were filed with the U.S. Equal Employment Opportunity Commission (EEOC), flat from the prior year, but up 9% compared to fiscal year 20231. As settlement volumes increase, demand is growing for more adaptable structures that can address the complexity of modern cases.

“For many non-physical injury cases, payees increasingly call for delayed or customized payments that traditional structures don’t support,” said Bejan Shirvani, head of Structured Settlements at MetLife. “This funding agreement solution expands the tools available to attorneys and brokers by combining greater flexibility in payment timing and structure with the strength of MetLife’s guarantees, helping support long-term financial security for claimants.”

Non-qualified assignments are commonly used to resolve claims that are not eligible for tax-free treatment under federal law by transferring payment obligations to an assignment company, allowing settlements to be paid over time. However, traditional structures are generally subject to Internal Revenue Code Section 72(u), which requires payments to begin within one year. The NQA-FA is not subject to these requirements, enabling deferred payments beyond one year and a broader range of designs that can align with future events or long-term financial needs.

The NQA-FA is available through MetLife Assignment Company, Inc. and issued by Metropolitan Tower Life Insurance Company.

About MetLife
MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates (“MetLife”), is one of the world’s leading financial services companies, providing insurance, annuities, employee benefits and asset management to help individual and institutional customers build a more confident future. Founded in 1868, MetLife has operations in more than 40 markets globally and holds leading positions in the United States, Asia, Latin America, Europe and the Middle East. For more information, visit www.metlife.com.

More News From MetLife, Inc.

Back to Newsroom

Key Takeaways MetLife launched NQA-FA to offer flexible payment options for non-physical injury settlements.The product targets claims involving employment disputes, discrimination and contract matters.Broader adoption could generate additional fee income and strengthen MetLife's client relationships. MetLife, Inc. (MET - Free Report) recently launched a new deferred-payment solution called the Non-Qualified Assignment Flex Agreement (NQA-FA), designed for settling non-physical injury claims. The product allows defendants and insurers to transfer future payment obligations to MetLife while giving claimants more flexibility in how and when they receive settlement proceeds.

Unlike traditional settlements that rely on annuities, NQA-FA is funded through a funding agreement, enabling customized payment schedules, deferred start dates and lump-sum payouts. The offering is aimed at cases involving employment disputes, wrongful termination, discrimination claims, contract disputes, punitive damages, environmental matters and certain professional liability claims.

Per MetLife, 88,201 workplace discrimination charges were filed with the U.S. EEOC in fiscal 2025, which remained flat year over year but increased 9% from fiscal 2023. The company expects the solution to expand settlement planning options while maintaining the security and reliability associated with MetLife's guarantees.

The product, issued by Metropolitan Tower Life Insurance Company, addresses a gap in the settlement market by giving parties more flexibility in resolving non-physical injury claims. Claimants can better match payments to future financial needs, while insurers gain another tool to settle cases efficiently.

For MetLife, the product will likely open a new source of fees by expanding its presence in the non-qualified settlement market. Greater flexibility may attract more settlement volume from insurers, law firms and claimants, supporting future business growth. The offering also strengthens MetLife’s competitive position. Broader adoption may generate incremental assets under management and additional settlement-related revenues over time, while deepening client relationships.

MET’s Price PerformanceMetLife shares have gained 10% year to date against the 4.1% fall of the industry it belongs to.

Image Source: Zacks Investment Research

Zacks Rank & Key PicksMetLife currently has a Zacks Rank #3 (Hold).

Investors interested in the broader insurance space may look at some better-ranked players like Hamilton Insurance Group, Ltd. (HG - Free Report) , Horace Mann Educators Corporation (HMN - Free Report) and CNO Financial Group, Inc. (CNO - Free Report) , each currently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Zacks Consensus Estimate for Hamilton Insurance’s current-year earnings is pegged at $4.10, which has witnessed one upward revision over the past 60 days and no downward movement. It beat earnings estimates in each of the trailing four quarters, with an average surprise of 84.8%. The consensus estimate for Hamilton Insurance’s 2026 revenues is pegged at $2.87 billion.

The consensus mark for Horace Mann Educators’ current-year earnings is pegged at $4.50 per share, which has witnessed one upward revision over the past 60 days and no movement in the opposite direction. Furthermore, the consensus estimate for HMN’s 2026 revenues indicates a 4% year-over-year increase.

The Zacks Consensus Estimate for CNO Financial’s current-year earnings is pegged at $4.46 per share, which indicates 9.3% year-over-year growth. It has witnessed one upward estimate revision against none in the opposite direction in the past month. CNO beat earnings estimates in each of the past four quarters, with an average surprise of 16.9%.